The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.
 
Nimit Singhal
Consulting or Advisory Role - Roche; Specialised Therapeutics
 
Darren Sigal
Stock and Other Ownership Interests - Celularity; Cend Therapeutics; Karyopharm Therapeutics; Novartis
Honoraria - Ipsen
Consulting or Advisory Role - Celularity; Cend Therapeutics
Speakers' Bureau - Ipsen
Research Funding - Abivax; ARIAD/Incyte; OBI Pharma
Patents, Royalties, Other Intellectual Property - Patent on "a method for treating neuroendocrine tumors" using TRK inhibitors.
 
Niall C. Tebbutt
Honoraria - Bristol-Myers Squibb; Pierre Fabre; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer
 
Aram F Hezel
Consulting or Advisory Role - Merck KGaA; Pfizer; QED Therapeutics; Taiho Pharmaceutical
 
Adnan Nagrial
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Sumit Lumba
No Relationships to Disclose
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Sheri Lynn Smith
Stock and Other Ownership Interests - 3M; Panbela Therapeutics
Consulting or Advisory Role - Actuate Therapeutics (Inst); Asymmetric Therapeutics; Celcuity (Inst); Humanetics (Inst); Inceptua (Inst); Medtronic (Inst); Panbela Therapeutics (Inst); Sun BioPharma (Inst); Tanner Pharma; Tolero Pharmaceuticals (Inst); Vanquish Oncology (Inst)
 
Suzanne Gagnon
Employment - Panbela Therapeutics; Sun BioPharma
Leadership - Sun Biopharma
Stock and Other Ownership Interests - Sun Biopharma
Consulting or Advisory Role - Cancer Prevention Pharmaceuticals; ProvePharm
Travel, Accommodations, Expenses - Sun BioPharma
 
Michael T. Cullen
Employment - Panbela Therapeutics
Leadership - Sun Biopharma
Stock and Other Ownership Interests - Sun Biopharma
Travel, Accommodations, Expenses - Sun Biopharma
 
Michael Walker
Employment - Panbela Therapeutics
Stock and Other Ownership Interests - Panbela Therapeutics
Consulting or Advisory Role - Panbela Therapeutics
Research Funding - Panbela Therapeutics
Patents, Royalties, Other Intellectual Property - Method of Dosing SBP-101
Travel, Accommodations, Expenses - Panbela Therapeutics